Genetic engineering of non-beta cells to release insulin upon feeding could
be a therapeutic modality for patients with diabetes. A tumor-derived K-ce
ll line was induced to produce human insulin by providing the cells with th
e human insulin gene linked tb the 5'-regulatory region of the gene encodin
g glucose-dependent insulinotropic polypeptide (GIP). Mice expressing this
transgene produced human insulin specifically in gut K cells. This insulin
protected the mice from developing diabetes and maintained glucose toleranc
e after destruction of the native insulin-producing beta cells.